The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ARTL | -56.52% | -93.59% | -42.27% | -99% |
| S&P | +19.61% | +98.99% | +14.75% | +166% |
Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded on May 2, 2011 and is headquartered in Solana Beach, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 0.0% |
| Market Cap | $7.25M | 67.7% |
| Market Cap / Employee | $1.21M | 0.0% |
| Employees | 6 | 0.0% |
| Net Income | -$3.22M | -32.4% |
| EBITDA | -$3.15M | -25.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $2.07M | 134.5% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.05M | -41.4% |
| Short Term Debt | $0.83M | 2406.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -165.62% | -82.8% |
| Return On Invested Capital | -155.59% | -90.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$0.60M | 70.9% |
| Operating Free Cash Flow | -$0.60M | 70.9% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.57 | 1.22 | 4.40 | 66.78 | 14624.90% |
| Price to Tangible Book Value | 4.12 | 4.75 | 21.06 | -31.39 | -1006.99% |
| Enterprise Value to EBITDA | 0.94 | -0.31 | -0.93 | -2.04 | -543.32% |
| Return on Equity | -87.1% | -134.5% | -190.7% | -356.5% | 302.41% |
| Total Debt | $0.11M | $0.10M | $0.10M | $0.88M | 631.67% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
